CJC-1295 Ipamorelin Dosage Research: What Was Given, to What, by Which Route

The short version

This page covers CJC-1295 Ipamorelin dosage as a research subject — what was given to which species, by which route, in published studies. It is not a how-to, and it carries no human protocol, because none has been validated for this pairing. Read it as a record, not a recipe.

The single most important number here is not a dose but a clock. The two peptides keep wildly different time. CJC-1295 with DAC, once injected, hooks onto a blood protein and lingers for days. The no-DAC form — called Mod GRF (1-29) — clears in about half an hour. Ipamorelin sits in between, gone within hours, with its GH peak around forty minutes after a dose. Knowing which CJC-1295 you are reading about changes everything that follows, so the half-life split leads — and no figure below is an instruction.

Cjc 1295 ipamorelin dosage in the literature

Cjc 1295 ipamorelin dosage has no validated human combination protocol; the published numbers belong to the single components, by species and route. For CJC-1295 with DAC, human Phase 1 pharmacokinetic studies administered 30 to 90 µg/kg subcutaneously ^[1]; GHRH-knockout mouse work used about 2 µg/day. The no-DAC form, Mod GRF (1-29), has no formal standalone human PK study and appears in research protocols modelled at roughly 100–200 µg per injection as a short pulsatile signal. For ipamorelin, rodent dosing spans 100 µg/kg three times daily in bone studies, 0.5 mg/kg/day for bone mineral, and 0.01–1 mg/kg intravenously for gut motility, with around 1 µg/kg plateauing the GH response in rodent models; no validated human PK has been published. Every one of those is a study parameter in an animal or early-phase context — not a human dose.

Cjc 1295 dac: the multi-day half-life

Cjc 1295 dac is the long-acting form, and its half-life is the reason it exists. The DAC — a maleimidopropionamide-lysine handle — covalently bonds to Cys34 of serum albumin after injection, turning the small peptide into an albumin-tethered one that the body clears slowly. In humans the result is a half-life on the order of ~6-8 days; in rats, albumin-bound peptide stayed detectable in plasma beyond 72 hours, and the bioconjugate raised GH AUC roughly 4-fold over two hours versus unmodified hGRF(1-29) ^[5]. Functionally, this means GH and IGF-1 stay elevated for days from a single dose ^[1] — a sustained signal, not a pulse, which is exactly the property the safety discussion on the effects page treats as a distinct exposure profile.

Mod grf 1-29: the 30-minute pulse

Mod grf 1-29 is CJC-1295 without DAC — the same modified GHRH(1-29) fragment, minus the albumin handle. Stripped of that anchor, it behaves like native GRF: a short, pulsatile GHRH signal with a half-life on the order of ~30 min, cleared by DPP-IV cleavage. The amino-acid substitutions that make it 'modified' slow that enzymatic breakdown somewhat, but without DAC there is no multi-day hold. The practical contrast is stark: where the DAC form holds the door open for days, Mod GRF (1-29) knocks once and is gone — a difference of two orders of magnitude in duration, and the single most consequential thing to get right when reading about CJC-1295.

Ipamorelin pharmacokinetics and the gaps

Ipamorelin's measured kinetics come from rodents: a plasma half-life under about two hours, with the peak GH response roughly forty minutes after a dose. No validated human half-life has been published — a real gap, not an omission, and one the orthopaedic and sports-medicine reviews of the class flag directly ^[11]. Routes studied across the pair include subcutaneous and intravenous injection, continuous subcutaneous infusion via osmotic minipump in rodent models, and intranasal delivery in rodent ipamorelin PK work. Where the DAC arm is engineered for duration, the ipamorelin arm is engineered for a clean, brief pulse — and pairing the two means the net GH exposure of any given schedule is, frankly, uncharacterized.

Handling and stability, in research context

Lyophilised (freeze-dried) peptide is stable frozen for extended periods. After reconstitution with bacteriostatic water — sterile water carrying 0.9% benzyl alcohol as a preservative — aqueous peptide solutions are kept refrigerated at 2–8 °C and degrade over weeks, chiefly via asparagine deamidation; the degradation products can be markedly less potent. Agitation and repeated freeze-thaw are avoided. GHRH analogues face DPP-IV cleavage in plasma, which is precisely what CJC-1295's substitutions and DAC were engineered to resist. This is standard laboratory-handling context for stored research peptides, recorded here for completeness — not a preparation or administration guide.